The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Longest survival follow-up ever reported for immunotherapy treatment in this setting
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Experts’ conclave to pave holistic approach to cancer management
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
Subscribe To Our Newsletter & Stay Updated
